5-(4-氟苯基)-3-甲基-1,2,4-恶二唑 | 59562-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(4-氟苯基)-3-甲基-1,2,4-恶二唑
• 英文名称: 3-methyl-5-(4'-fluorophenyl)-1,2,4-oxadiazole
• 英文别名: 3-methyl-5-(4-fluorophenyl)-1,2,4-oxadiazole；5-(4-fluoro-phenyl)-3-methyl-[1,2,4]oxadiazole；5-(4-fluorophenyl)-3-methyl-1,2,4-oxadiazole
• CAS: 59562-68-4
• 化学式: C₉H₇FN₂O
• mdl: MFCD09261229
• 分子量: 178.166
• InChiKey: YTSHBDOOEVBVHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(4-氟苯基)-3-甲基-1,2,4-恶二唑 在 4-二甲氨基吡啶 、 碘 、 potassium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 264.0h， 生成 3-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)-5-(iodomethyl)oxazolidin-2-one
  参考文献：
  名称：

  New linezolid-like 1,2,4-oxadiazoles active against Gram-positive multiresistant pathogens

  摘要：

  The synthesis and the in vitro antibacterial activity of novel linezolid-like oxadiazoles are reported. Replacement of the linezolid morpholine C-ring with 1,2,4-oxadiazole results in an antibacterial activity against Staphylococcus aureus both methicillin-susceptible and methicillin-resistant comparable or even superior to that of linezolid. While acetamidomethyl or thioacetoamidomethyl moieties in the C(5) side-chain are required, fluorination of the phenyl B ring exhibits a slight effect on an antibacterial activity but its presence seems to reduce the compounds cytotoxicity. Molecular modeling performed using two different approaches - FLAP and Amber software - shows that in the binding pose of the newly synthesized compounds as compared with the crystallographic pose of linezolid, the 1,2,4-oxadiazole moiety seems to perfectly mimic the function of the morpholinic ring, since the H-bond interaction with U2585 is retained. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.069
• 作为产物：
  描述：

  对氟苯甲酰氯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 生成 5-(4-氟苯基)-3-甲基-1,2,4-恶二唑
  参考文献：
  名称：

  针对革兰氏阳性多耐药病原体的新型强效抗菌剂：利奈唑胺样1,2,4-恶二唑中侧链修饰和手性的影响

  摘要：

  研究了利奈唑胺样1,2,4-恶二唑中侧链修饰和手性的影响，以设计出针对革兰氏阳性多药耐药病原体的新型有效抗菌剂。所采用的策略涉及分子建模方法，新设计化合物的合成和生物学评估，对映异构体分离和绝对构型分配。设计的（S）-1-（（3-（4-（3-甲基-1,2,4-恶二唑-5-基）苯基）-恶唑烷丁-2-one-5- ））（甲基）-3-甲基硫脲和（S）-1-（（3-（3-氟-4-（3-甲基-1,2,4-恶二唑-5-基）苯基）-恶唑烷-2-一（5-基）甲基）-3-甲基硫脲对耐多药的利奈唑胺菌株的耐药性高于利奈唑胺。

  DOI：

  10.1016/j.bmc.2014.10.037

文献信息

• [EN] PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS<br/>[FR] LIGANDS DE RECEPTEURS HISTAMINIQUES A BASE DE DERIVES PYRROLIDINIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2006040192A1

  公开（公告）日：2006-04-20

  The present invention relates to pyrrolidine derivatives of formula (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的吡咯烷衍生物公式(I)，它们的制备方法，含有它们的组合物及其在治疗神经和精神障碍中的用途。
• DIAZA-BENZOFLUORANTHRENE COMPOUNDS
  申请人：HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY

  公开号：US20180016270A1

  公开（公告）日：2018-01-18

  Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.

  揭示了一系列二氮杂苯并芴类化合物。本发明特别涉及一种由式(I)表示的化合物，其药学上可接受的盐或互变异构体。
• [EN] NOVEL 1, 2, 4-OXADIAZOL COMPOUNDS ACTIVE AGAINST GRAM-POSITIVE PATHOGENS<br/>[FR] NOUVEAUX COMPOSÉS 1, 2, 4-OXADIAZOL ACTIFS CONTRE DES PATHOGÈNES À GRAM POSITIF
  申请人：UNIVERSIT DEGLI STUDI DI MILANO BICOCCA

  公开号：WO2014141218A1

  公开（公告）日：2014-09-18

  The present invention relates to new oxazolidinone compounds of general formula (I) having antibiotic activity even against multiresistant bacterial strains (I).

  本发明涉及一种具有抗生素活性的新的氧唑啉酮化合物，即一般公式（I）中的化合物，甚至对多重耐药细菌菌株也具有抗生素活性。
• Pyrrolidine Derivatives as Histamine Receptors Ligands
  申请人：Bruton Gordon

  公开号：US20080045506A1

  公开（公告）日：2008-02-21

  The present invention relates to pyrrolidine derivatives of formula (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的公式（I）的吡咯烷衍生物，其制备过程，包含它们的组合物以及它们在治疗神经系统和精神疾病中的应用。
• Potassium Channel Inhibitors
  申请人：Trotter B. Wesley

  公开号：US20090233897A1

  公开（公告）日：2009-09-17

  The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

  本发明涉及具有结构的化合物，可用作钾通道抑制剂以治疗心律失常等。